I am very surprised with the price action after hours...it appears no one really cares about DEPO.
I bought more today. I think this company is a potential acquisition candidate. JMHO.
Sentiment: Strong Buy
Antares Pharma Announces LEO Pharma’s Launch of OTREXUP (Methotrexate) Injection to Dermatologists for Adults with Psoriasis
-- LEO Pharma: A Global Leader In Dermatology And Topical Treatments For Psoriasis --
Antares Pharma, Inc.
17 minutes ago
I was going to buy into the secondary and then decided against it. $82/share is too rich ..valuation is way too high. I believeFEYE is cutting edge and has great potential, but i think it might get cheaper given the current geo-political climate.
I'll probably feel stupid tomorrow if it runs up to $97.
Yes. I owned over 1000 BPAX and after the deal was done I now have 27 shares. My cost is $60 plus per share....I have a long wait unless ANI comes out with a blockbuster.
Latest articel about KERX:
Happy New Year to all.
I've owned CVM for a long time and quite frankly wonder if this is just a bankruptcy waiting to happen.
I had great faith in the company a few years ago but now cannot see the future potential of the research.
Bought this in my IRA so I can't even offset gains with the loss.
I'll be here until the bitter end or sweet surprise...hoping for the later.
I have invested in many biotechs..some have been blockbusters and some just went bust..it's the nature of the beast...high risk/ high reward.
Happy Holidays to any serious investors on this MB...
NEW YORK, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,609,896. The patent, which expires in 2024, claims orally administrable forms of Zerenex prepared from ferric citrate having a BET active surface area greater than about 16 sq. m/g. The active pharmaceutical ingredient (API) of Zerenex is ferric citrate having a BET surface area substantially above this surface area threshold.
This newly issued patent further enhances the Company's key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298 and 8,338,642. These U.S. patents expire in 2024, without patent term extension, and contain composition and method of use claims covering Zerenex.
Ron Bentsur, Chief Executive Officer of Keryx, commented, "We believe that our portfolio of patents will